Health
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial – The Lancet
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients
with NAFLD and constipation. Further studies are necessary to better define the efficacy
and tolerability of lubiprostone in patients with NAFLD without constipation.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General13 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News22 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia